We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
Books
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
» Boehringer Sues Amneal to Block Generic Aggrenox
Boehringer Sues Amneal to Block Generic Aggrenox
August 13, 2014
Pharmaceuticals
Commercial Operations
Boehringer Ingelheim is suing Amneal Pharmaceuticals over its bid to make a generic version of the brand manufacturer’s anti-stroke drug Aggrenox.
To View This Article:
Login
Email
Password
Register
Remember Me
Forgot your password?
Subscribe To Generic Line
Buy This Article Now
Add this article to your cart for $40.00
Upcoming Events
18
Oct
MAGI's Clinical Research vConference — Fall 2021
27
Oct
Five Steps to TMF “Inspection Readiness”
28
Oct
Master Your Clinical Trial Budgets: A Step-by-Step Guide to Smarter Budgeting
03
Nov
Real-World Evidence in Medical Device Submissions
09
Nov
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
11
Nov
The MDSAP Audit Process: Latest Developments and Best Practices
Featured Products
Biological Risk Evaluation and Management for Medical Devices
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
Featured Stories
Continuous Manufacturing of Pharmaceuticals Bill Clears House
HistoSonics Gets Breakthrough Device Designation for Sonic Beam Cancer Therapy
Walensky Endorses CDC Panel Greenlight for Moderna, J&J Booster Vaccinations, and Mix and Match
Venus Concept Gets 510(k) Clearance for Its Pain Treatment Device
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
